Ambrx Biopharma Inc. (AMAM): Price and Financial Metrics
AMAM Price/Volume Stats
| Current price | $28.00 | 52-week high | $28.15 |
| Prev. close | $27.98 | 52-week low | $6.55 |
| Day low | $27.98 | Volume | 1,439,600 |
| Day high | $28.00 | Avg. volume | 2,123,967 |
| 50-day MA | $25.33 | Dividend yield | N/A |
| 200-day MA | $15.99 | Market Cap | 1.77B |
AMAM Stock Price Chart Interactive Chart >
Ambrx Biopharma Inc. (AMAM) Company Bio
Ambrx Biopharma Inc., a clinical-stage biologics company, focuses on discovering and developing engineered precision biologics (EPBs) using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 ADC, which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction (GEJ) cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug (IND)-enabling studies for the treatment of renal cell carcinoma (RCC) and other cancers, as well as other multiple product candidates targeting immuno-oncology applications. In addition, it is developing ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the à and gamma receptors on the cytotoxic T cell; and ARX822, a fab-small molecule bispecific that is in preclinical development for cancers. The company has license agreements with NovoCodex, Bristol Myers Squibb Company, Agensys, Inc., Sino Biopharmaceutical Co., Ltd., University of California, BeiGene, Ltd., The Scripps Research Institute and The California Research Institute of Biomedical Research, AbbVie Inc., Astellas Pharma Inc., and Elanco Animal Health. Ambrx Biopharma Inc. was founded in 2003 and is based in La Jolla, California.
Latest AMAM News From Around the Web
Below are the latest news stories about AMBRX BIOPHARMA INC that investors may wish to consider to help them evaluate AMAM as an investment opportunity.
Ambrx to be Added to the NASDAQ Biotechnology Index (NBI)SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx, (NASDAQ: AMAM), today announced that the Company will be added to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective prior to the market open on Monday, December 18, 2023. “2023 has been a transformational year for Ambrx, especially for our publicly held securities. We voluntarily transferred to Nasdaq from the New York Stock Exchange, we changed our parent company domicile to Delaware from the Cayman Islands and |
Ambrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate CancerCohort 9 Following completion of the 21-day observation period at 3.4 mg/kg (Cohort 9), no dose limiting toxicities (DLTs) or serious adverse events (SAEs) were observed Two patients in Cohort 9 experienced rapid PSA reduction at three weeks post-treatment following the first ARX517 dose Cohort 8 The cohort (2.88 mg/kg) is now fully enrolled with 20 patients Recommended phase 2 dose expected by early next year SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx (NASDAQ: |
Ambrx Announces ARX517, a PSMA-Targeted ADC, Demonstrates a Promising 52% PSA50 (≥50% Reduction) and a Highly Differentiated Safety and PK Profile in Patients with mCRPC, who Progressed on Multiple FDA-Approved TreatmentsNewly published data from the Phase 1 portion of the on-goingPhase 1 / 2 APEX-01 trial provide the following key points: Multiple efficacy endpoints demonstrate consistent and promising anti-cancer activity at therapeutic doses of 2.0 – 2.88 mg/kg (Cohorts 6-8) in heavily pretreated patients (median of 4 and maximum of 13 prior lines of therapy): 52% (12/23) of patients experienced a ≥50% PSA reduction81% (17/21) of patients experienced ≥50% circulating tumor DNA reduction50% (3/6) of patients w |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayIt's time for another dive into the biggest pre-market stock movers as we list out the top stocks worth watching on Tuesday! |
Ambrx Provides Safety and Efficacy Data from Ongoing Phase 1/2 APEX-01 Trial of ARX517 in mCRPC at ESMO CongressNewly published abstract regarding dose escalation patients provides key updates including: ≥50% PSA reduction observed across putative therapeutic dose levels ≥2.0 mg/kg – 3 of 3 in Cohort 6 (2.0 mg/kg), 2 of 3 in Cohort 7 (2.4 mg/kg) and 2 of 3 in Cohort 8 (2.88 mg/kg)No drug-related severe adverse events (SAEs) and no dose limiting toxicities (DLTs) observed in any cohortPharmacokinetic (PK) data indicated strong ADC stability preventing premature release of anticancer payload Ambrx to host a |
AMAM Price Returns
| 1-mo | N/A |
| 3-mo | 1.27% |
| 6-mo | 232.15% |
| 1-year | 139.32% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 96.63% |
| 2023 | 527.31% |
| 2022 | -74.86% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...